Xu Haiyun graduated from Peking Union Medical College in July 1996 and obtained a Doctoral degree in Medicine. He currently works as a full professor at Department of Psychiatry, School of Mental Health, Wenzhou Medical University, China. Starting from September, 1996, he worked in Medical College of Wisconsin, USA, as a post-doctoral research fellow in Neurobiology. In the spring of 2000, he moved to Canada and worked at Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, as a senior research associate conducting basic research in Biological Psychiatry and Psychopharmacology fields. In September, 2006, he was employed by Southern Illinois University Carbondale, US, as an assistant professor and principal investigator continuing his research interests in Biological Psychiatry and Psychopharmacology, in addition to teaching medical students. In september, 2011, he came back to China and worked in Shantou University Medical College, as a full professor supervising basic and clinical research in Psychiatry and Psychopharmacology, in addition to teaching medical students, supervising graduate students and post-doctoral research fellows, as well as functing as the executive director of a Joint Laboratory of Biological Psychiatry supported by Shantou University, China and University of Mannitoba, Canada. During September 2017 - August 2018, he worked as the Research Director and Acting Academic Vice President of Guangdong Technion - Israel Institute of Technology, China. Since October 2019, he has served as a full professor and the head of the Department of Psychiatry in Wenzhou Medical University, and the chief clinical researcher of Wenzhou Kangning Hospital. In addition, he has served as the deputy director of the Zhejiang Provincial Clinical Research Center for mental health and a member of the academic committee of the center, as well as a member of the academic committee of the Zhejiang Provincial Key Laboratory of Drug Rehabilitation Research. During the past decades, he participated in and presided over multiple scientific research projects funded by the NIH of the United States, the MRC and CIHR of Canada, the Science and Technology Departments of Guangdong Province and Zhejiang Province, and the National Natural Science Foundation of China. He has supervised over 30 graduate students in Master and doctoral programs, as well as postdoctoral research fellows. He for the first time established the white matter damage model of schizophrenia, reported promoting effects of quetiapine on the development of oligodendrocytes in both the in vivo and vitro experiments. He is the first one to propose the concept of neuron-glial integrity in the brain and evaluated the integrity by means of proton MRS in biological psychiatry research. He has published >100 papers in academic journals such as Mol Psychiatry, Neuropsychopharmacology, Neurosci Biobehav Rev., Transl Psychiatry, and so on. He has been serving as the associate editor of Biochem & Cell Biol and editorial boards of 16 international academic journals. He was ranked as a top scientist in the field of neuroscience worldwide in 2023 and 2024.